Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Burr Vonmaur

Plastic and Reconstructive Surgery Corona Del Mar, CA Medical Doctor

NPI 1619094893 CMS profile 864421

1101 Bayside Dr Ste 100, Suite 100, Corona Del Mar, CA 92626

Open in the dashboard

General payments

$3,000

102 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Burr Vonmaur of Corona Del Mar, CA is reported in the CMS Open Payments database as having received $3,000 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $16 1
2023 General $191 10
2022 General $1,047 30
2021 General $677 22
2020 General $719 20
2019 General $349 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Burr Vonmaur
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Burr Vonmaur were reported at $0. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Burr Vonmaur Plastic and Reconstructive Surgery median Middle half National median
2019 $349 $335 $121–$1,264 $163
2020 $719 $162 $57–$417 $114
2021 $677 $245 $89–$735 $132
2022 $1,047 $325 $120–$932 $149
2023 $191 $343 $129–$999 $160
2024 $16 $390 $141–$1,085 $164
2025 $0 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Sientra, Inc. $1,554 30 payments
  2. Allergan Inc. $1,030 52 payments
  3. AbbVie, Inc. $174 10 payments
  4. Boston Scientific Corporation $51 1 payment
  5. Galderma Laboratories, L.P. $50 3 payments
  6. Tepha Inc $39 1 payment
  7. Apyx Medical Corporation $38 2 payments
  8. Integra LifeSciences Corporation $33 1 payment
  9. TELA Bio, Inc. $16 1 payment
  10. Smith+Nephew, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,000 102 payments
Products named General payments · program years 2019–2024
  1. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $1,554 30 payments
  2. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $384 22 payments
  3. NATRELLE $184 10 payments
  4. BOTOX COSMETIC $173 12 payments
  5. BOTOX $135 7 payments
  6. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $109 6 payments
  7. SPECTRA WAVEWRITER $51 1 payment
  8. GalaFLEX $39 1 payment
  9. DuraSorb Monofilament Mesh $33 1 payment
  10. NAMENDA $20 1 payment
  11. Other $45 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record